vs
Jaguar Health, Inc.（JAGX）与High Roller Technologies, Inc.（ROLR）财务数据对比。点击上方公司名可切换其他公司
High Roller Technologies, Inc.的季度营收约是Jaguar Health, Inc.的1.9倍（$6.3M vs $3.2M），High Roller Technologies, Inc.净利率更高（58.4% vs -717.2%，领先775.6%），Jaguar Health, Inc.同比增速更快（-7.8% vs -16.4%）
Jaguar Health, Inc.是一家处于商业化阶段的生物制药企业，专注于开发和商业化植物源处方药物，覆盖人用和动物用两大领域，核心管线针对胃肠道领域未被满足的医疗需求，主要市场覆盖北美及部分欧洲区域。
该企业主营游乐设施业务，凭借气动驱动技术打造各类游乐设备，专业从事过山车设计研发，在游乐设施设计制造领域拥有相关技术积累与行业经验。
JAGX vs ROLR — 直观对比
营收规模更大
ROLR
是对方的1.9倍
$3.2M
营收增速更快
JAGX
高出8.6%
-16.4%
净利率更高
ROLR
高出775.6%
-717.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $6.3M |
| 净利润 | $-23.2M | $3.7M |
| 毛利率 | 32.0% | — |
| 营业利润率 | -656.6% | 1.3% |
| 净利率 | -717.2% | 58.4% |
| 营收同比 | -7.8% | -16.4% |
| 净利润同比 | -133.9% | 831.9% |
| 每股收益（稀释后） | $10.27 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAGXROLR
| Q4 25 | $3.2M | — | ||
| Q3 25 | $3.1M | $6.3M | ||
| Q2 25 | $3.0M | $6.9M | ||
| Q1 25 | $2.2M | $6.8M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $3.1M | $7.5M | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $2.4M | — |
净利润JAGXROLR
| Q4 25 | $-23.2M | — | ||
| Q3 25 | $-9.5M | $3.7M | ||
| Q2 25 | $-10.4M | $-592.0K | ||
| Q1 25 | $-10.5M | $-3.3M | ||
| Q4 24 | $-9.9M | — | ||
| Q3 24 | $-9.9M | $-501.0K | ||
| Q2 24 | $-9.5M | — | ||
| Q1 24 | $-9.2M | — |
毛利率JAGXROLR
| Q4 25 | 32.0% | — | ||
| Q3 25 | 82.7% | — | ||
| Q2 25 | 82.3% | — | ||
| Q1 25 | 76.7% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 82.6% | — | ||
| Q2 24 | 84.3% | — | ||
| Q1 24 | 81.7% | — |
营业利润率JAGXROLR
| Q4 25 | -656.6% | — | ||
| Q3 25 | -234.8% | 1.3% | ||
| Q2 25 | -268.8% | -7.2% | ||
| Q1 25 | -425.5% | -47.4% | ||
| Q4 24 | -232.5% | — | ||
| Q3 24 | -233.7% | -6.3% | ||
| Q2 24 | -264.5% | — | ||
| Q1 24 | -349.4% | — |
净利率JAGXROLR
| Q4 25 | -717.2% | — | ||
| Q3 25 | -308.2% | 58.4% | ||
| Q2 25 | -349.3% | -8.5% | ||
| Q1 25 | -472.6% | -48.4% | ||
| Q4 24 | -282.7% | — | ||
| Q3 24 | -317.1% | -6.7% | ||
| Q2 24 | -348.8% | — | ||
| Q1 24 | -392.4% | — |
每股收益（稀释后）JAGXROLR
| Q4 25 | $10.27 | — | ||
| Q3 25 | $-6.28 | $0.39 | ||
| Q2 25 | $-10.26 | $-0.07 | ||
| Q1 25 | $-16.70 | $-0.39 | ||
| Q4 24 | $-14.62 | — | ||
| Q3 24 | $-1.05 | $-0.07 | ||
| Q2 24 | $-4.04 | — | ||
| Q1 24 | $-0.06 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $968.0K | $2.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-18.7M | $6.6M |
| 总资产 | $38.3M | $16.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JAGXROLR
| Q4 25 | $968.0K | — | ||
| Q3 25 | $3.5M | $2.7M | ||
| Q2 25 | $2.2M | $2.7M | ||
| Q1 25 | $5.7M | $3.5M | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $13.3M | $1.3M | ||
| Q2 24 | $16.0M | — | ||
| Q1 24 | $11.7M | — |
股东权益JAGXROLR
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $4.4M | $6.6M | ||
| Q2 25 | $6.9M | $2.6M | ||
| Q1 25 | $830.0K | $2.8M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $13.1M | $-779.0K | ||
| Q2 24 | $16.6M | — | ||
| Q1 24 | $11.8M | — |
总资产JAGXROLR
| Q4 25 | $38.3M | — | ||
| Q3 25 | $49.5M | $16.0M | ||
| Q2 25 | $48.3M | $12.3M | ||
| Q1 25 | $51.5M | $12.8M | ||
| Q4 24 | $53.4M | — | ||
| Q3 24 | $58.5M | $12.9M | ||
| Q2 24 | $61.5M | — | ||
| Q1 24 | $55.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-78.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-90.0K |
| 自由现金流率自由现金流/营收 | — | -1.4% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流JAGXROLR
| Q4 25 | $-5.5M | — | ||
| Q3 25 | — | $-78.0K | ||
| Q2 25 | — | $-840.0K | ||
| Q1 25 | $-7.3M | $-3.6M | ||
| Q4 24 | $-7.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-7.0M | — |
自由现金流JAGXROLR
| Q4 25 | — | — | ||
| Q3 25 | — | $-90.0K | ||
| Q2 25 | — | $-845.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率JAGXROLR
| Q4 25 | — | — | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | — | -12.2% | ||
| Q1 25 | — | -53.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度JAGXROLR
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率JAGXROLR
| Q4 25 | — | — | ||
| Q3 25 | — | -0.02× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAGX
| Human Health Segment | $3.2M | 97% |
| Other | $83.0K | 3% |
ROLR
| Net Gaming Revenue | $4.9M | 77% |
| Net Revenue Noncore Services | $1.4M | 23% |
